O'PKA ARTERIAL GIPERTENZIYASIDA 6 DAQIQALIK YURISH TESTI VA KARDIOPULMONAL TESTNING QIYOSIY TAHLILI
DOI:
https://doi.org/10.5281/zenodo.20588152Keywords:
pulmonary arterial hypertension, 6-minute walk test, cardiopulmonary exercise testing, comparative analysis, risk stratification, prognosis.Abstract
In pulmonary arterial hypertension (PAH), two main approaches are used for exercise tolerance assessment: the 6-minute walk test (6MWT) and cardiopulmonary exercise test (CPET). This review provides a comparative analysis of both tests regarding diagnostic accuracy, prognostic value, practical convenience, and clinical application. While 6MWT is inexpensive, widely available, and a standardized PAH risk stratification parameter, it provides limited physiological information compared to CPET. Both tests should be viewed as complementary tools. Developing measures to extend survival and improve the quality of life in patients with pulmonary arterial hypertension requires the extensive use of 6MWT and CPET data. ROC analysis demonstrates that CPET parameters (AUC approximately 0.84) offer statistically superior prognostic accuracy compared to 6MWT (AUC approximately 0.71). However, 6MWT better reflects daily physical activity and is safe for all patient groups including severe functional class IV patients. Current guidelines recommend routine 6MWT every 3–6 months, while CPET is reserved for initial comprehensive assessment and complex clinical decision-making.References
Galie N., Humbert M., Vachiery J.L. et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618–3731.
Miyamoto S., Nagaya N., Satoh T. et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Am J Respir Crit Care Med. 2000;161(2):487–492.
ATS Committee. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111–117.
ATS/ACCP Statement on Cardiopulmonary Exercise Testing. Am J Respir Crit Care Med. 2003;167(2):211–277.
Sun X.G., Hansen J.E., Oudiz R.J., Wasserman K. Exercise pathophysiology in patients with primary pulmonary hypertension. Circulation. 2001;104(4):429–435.
Kylhammar D., Kjellstrom B., Hjalmarsson C. et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J. 2018;39(47):4175–4181.
Wensel R., Opitz C.F., Anker S.D. et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation. 2002;106(3):319–324.
Humbert M., Sitbon O., Yaici A. et al. Survival in incident and prevalent cohort of patients with pulmonary arterial hypertension. Eur Respir J. 2010;36:549–555.
Barst R.J., McGoon M., McLaughlin V. et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2003;41(12):2119–2125.
Benza R.L., Miller D.P., Barst R.J. et al. An evaluation of long-term survival from time of diagnosis in PAH from the REVEAL Registry. Chest. 2012;142(2):448–456.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Innovative Academy RSC
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
